Giant Cell Arteritis

Giant Cell Arteritis — scientific infographic poster
  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Clinical Manifestations
  5. Diagnosis
  6. ACR/EULAR 2022 Classification Criteria
  7. Treatment
  8. GCA–PMR Overlap
  9. Prognosis and Monitoring
  10. Key Research Papers
  11. Connections

Overview

Giant cell arteritis (GCA) is the most common primary systemic vasculitis in adults over the age of 50 in developed countries. It is a granulomatous inflammatory disease affecting large and medium-sized vessels, with a particular predilection for branches of the external and internal carotid arteries, the aorta, and its major branches. The condition was formerly known as "temporal arteritis" because of its frequent involvement of the temporal arteries, but this older name has largely been replaced as the full scope of large-vessel involvement became recognized. GCA affects women three times more often than men, with an overall incidence of 15 to 30 per 100,000 individuals over age 50, and occurs almost exclusively in people of Caucasian descent, particularly those of Northern European ancestry.

Cranial GCA — involving the temporal, ophthalmic, posterior ciliary, and vertebral arteries — is the most clinically urgent form of the disease. Inflammation and occlusion of the posterior ciliary arteries causes anterior ischemic optic neuropathy (AION), which is the leading cause of sudden, permanent vision loss in adults over 50. Because visual loss, once established, is almost never reversible, GCA with visual symptoms is treated as a true eye emergency (an ophthalmologic emergency). Prompt recognition and immediate initiation of high-dose corticosteroids before further ischemic events occur is the most critical intervention in clinical management.

Large-vessel GCA represents a second major disease phenotype in which granulomatous inflammation extends to the aorta, subclavian, axillary, and other proximal arteries. Patients with large-vessel involvement may present with arm claudication, blood pressure asymmetry between limbs, bruits over affected vessels, and, as a late complication, thoracic aortic aneurysm. Large-vessel GCA is often under-recognized clinically and may be identified incidentally on imaging studies performed for other indications. Some patients have overlapping cranial and large-vessel involvement, while others present exclusively with one phenotype.

Epidemiology

GCA occurs almost exclusively in individuals over age 50, with the mean age at onset typically ranging from 72 to 76 years. The disease is extraordinarily rare below age 50. Incidence rises sharply with advancing age, and the highest population-based rates have been documented in Olmsted County, Minnesota — a predominantly Scandinavian-descent cohort — where rates approach 29 per 100,000 individuals over age 50. Rates are substantially lower in Mediterranean European populations and are rare in African American, Asian, and Hispanic populations. This striking geographic and ethnic gradient strongly implicates both genetic and environmental determinants.

A genetic predisposition is well established. The HLA-DRB1*04 allele — particularly the shared epitope characteristic of rheumatoid arthritis susceptibility — is significantly associated with GCA and may influence disease expression and severity. Non-MHC genetic loci in immune regulatory pathways have also been identified in genome-wide association studies. Environmental triggers, possibly including certain infectious agents, have been proposed based on reports of seasonal clustering and geographic cycles in incidence, though no specific pathogen has been confirmed.

The lifetime risk of developing GCA is approximately 1% in women and 0.5% in men, reflecting the marked female predominance observed across all populations studied. Concurrent polymyalgia rheumatica (PMR) occurs in 40 to 50% of GCA patients at some point during their illness. Conversely, approximately 15 to 20% of patients diagnosed with pure PMR will eventually develop clinical features of GCA, and subclinical large-vessel vasculitis detectable on imaging may be present in a higher proportion of PMR patients. The two conditions share pathophysiologic mechanisms and likely represent a disease spectrum rather than entirely distinct entities.

Pathophysiology

The initiating event in GCA is thought to occur at the adventitial vasa vasorum — the small blood vessels that supply the walls of large arteries. Mature dendritic cells residing in the adventitia become inappropriately activated, possibly in response to an environmental antigen, and recruit CD4-positive T lymphocytes into the vessel wall. These T cells differentiate along both Th1 and Th17 pathways. Th1 cells produce interferon-gamma (IFN-γ), which drives macrophage activation and the formation of epithelioid granulomata containing multinucleated giant cells — the histological hallmark of the disease. Th17 cells, producing IL-17, contribute to a distinct inflammatory axis that may be relatively more steroid-resistant. Interleukin-6, produced in large quantities by activated macrophages and stromal cells, drives the systemic inflammatory response and accounts for the pronounced elevation of acute-phase reactants (erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)) characteristic of active GCA.

Activated macrophages in the media and intima of affected vessels produce platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), which stimulate smooth muscle cell proliferation and neoangiogenesis within the vessel wall. This process leads to progressive intimal hyperplasia and luminal stenosis, which is the final common pathway for the ischemic complications of GCA — including visual loss, jaw claudication, scalp necrosis, and stroke. The fragmentation of the internal elastic lamina, prominently visible on histology, is a direct consequence of matrix metalloproteinase release by activated macrophages and contributes to the structural disruption of the arterial wall.

The anatomical distribution of GCA reflects the biology of the vasa vasorum. Arteries with rich adventitial vasa vasorum — particularly the superficial temporal, posterior ciliary, ophthalmic, vertebral, subclavian, and aortic wall — are most vulnerable to inflammatory infiltration. Conversely, capillaries, venules, and vessels lacking a vasa vasorum are spared. This explains why GCA does not cause glomerulonephritis or cutaneous vasculitis despite being a systemic inflammatory disease. The selectivity of vascular involvement has important implications for understanding disease complications and targeting therapy.

Clinical Manifestations

The hallmark presentation of cranial GCA combines new-onset headache with one or more features of cranial ischemia or scalp and artery tenderness. The headache is typically described as temporal, often throbbing or boring in character, and may be severe and unremitting. Scalp tenderness — particularly tenderness over the course of the temporal artery — is frequently reported; patients may note discomfort when combing their hair or wearing a hat. On physical examination, the temporal artery may be thickened, nodular, pulseless, or exquisitely tender. These findings, when present, are highly suggestive of the diagnosis, though their absence does not exclude it.

Jaw claudication — pain or fatigue of the jaw muscles (masseter and temporalis) that comes on during chewing and is relieved by rest — is one of the most specific symptoms of GCA, occurring in approximately 40 to 50% of patients. It results from ischemia of the muscles of mastication supplied by branches of the external carotid artery. Tongue claudication and difficulty swallowing are less common but follow the same ischemic mechanism. Visual symptoms represent the most feared manifestation of GCA. Transient monocular visual loss (amaurosis fugax) may herald impending permanent visual loss. Established visual loss due to anterior ischemic optic neuropathy — caused by occlusion of the posterior ciliary arteries supplying the optic nerve head — typically presents as sudden, painless, monocular vision loss, often described as a curtain falling or a portion of the visual field going dark. Diplopia due to ischemia of extraocular muscles or cranial nerve VI palsy also occurs.

Constitutional symptoms are present in the majority of patients and may dominate the clinical picture before cranial symptoms emerge. Fatigue, malaise, unintentional weight loss, low-grade fever, and night sweats are common. An elevated erythrocyte sedimentation rate in an elderly patient with new headache and constitutional symptoms is a classic reason for doctors to consider GCA. Polymyalgia rheumatica — aching and morning stiffness of the shoulder and hip girdles — coexists in 40 to 50% of GCA patients and may be the presenting complaint.

Large-vessel GCA presents with symptoms referable to the subclavian, axillary, and brachial arteries: arm claudication with exertion, asymmetric blood pressure between the two arms (a difference exceeding 10 mmHg is clinically significant), subclavian or axillary bruits on auscultation, and reduced or absent radial pulses. Aortic involvement may be clinically silent initially but carries a 2- to 3-fold increased lifetime risk of thoracic aortic aneurysm compared with the general population — a late complication requiring long-term cardiovascular surveillance. Some patients present primarily with systemic inflammation and fever of unknown origin without cranial features, underscoring the protean nature of this disease.

Diagnosis

Laboratory evaluation in active GCA typically reveals a markedly elevated erythrocyte sedimentation rate — most commonly greater than 50 mm/hr and frequently exceeding 100 mm/hr — combined with elevated C-reactive protein. A normal erythrocyte sedimentation rate does not exclude GCA; approximately 5 to 10% of biopsy-proven cases present with a normal erythrocyte sedimentation rate, and C-reactive protein may be more sensitive in this context. Additional findings include normochromic normocytic anemia of chronic inflammation, reactive thrombocytosis, elevated alkaline phosphatase, and hypoalbuminemia. These are markers of systemic inflammation and are not specific to GCA.

Temporal artery biopsy remains the gold standard for diagnosis. A segment of at least 1.5 to 3 cm of the temporal artery is usually removed to maximize the yield; shorter segments increase the risk of missing skip lesions. Histological findings of GCA include transmural inflammation with lymphocytes, macrophages, and multinucleated giant cells, fragmentation or disruption of the internal elastic lamina, and intimal hyperplasia with luminal narrowing. Skip lesions — segments of normal artery interspersed with involved segments — occur in approximately 5% of cases, which is the rationale for considering contralateral biopsy when the first biopsy is negative despite strong clinical suspicion. A critical practical point: corticosteroids do not immediately eliminate histological changes, and biopsy remains diagnostically positive for at least 2 weeks after initiation of treatment. The 2018 EULAR recommendations state that high-dose glucocorticoid therapy (40–60 mg/day prednisone-equivalent) "should be initiated immediately" in active GCA, so treatment of a patient with threatened vision is not held back while biopsy results are awaited.

Imaging has transformed the diagnostic workup of GCA, particularly in centers with expertise in vascular ultrasound. Duplex ultrasonography of the temporal and axillary arteries demonstrating the "halo sign" — a concentric, hypoechoic ring of wall thickening surrounding the artery lumen, visible in longitudinal and transverse planes and not compressible with probe pressure — is now recognized by ACR/EULAR guidelines as an alternative to biopsy in experienced hands. FDG-PET/computed tomography (CT) is the preferred imaging modality for detecting large-vessel GCA, demonstrating increased metabolic activity along the aortic wall, subclavian, and axillary arteries. Magnetic resonance imaging (MRI) and MRA can also characterize vessel wall inflammation and luminal changes. Color Doppler ultrasound, positron emission tomography (PET), and magnetic resonance imaging are complementary; choice of modality depends on the clinical phenotype (cranial vs. large-vessel) and local expertise.

ACR/EULAR 2022 Classification Criteria

The American College of Rheumatology and EULAR jointly published updated classification criteria for GCA in 2022. These criteria were validated for use in clinical research — for classifying patients, not as standalone diagnostic criteria — a distinction that is clinically important. Age 50 or older at diagnosis is an absolute requirement, and classification applies to a patient with clinical evidence of vasculitis after other causes have been reasonably excluded.

The criteria use a point-based scoring system:

A total score of 6 or more points classifies the patient as having GCA (Ponte 2022). The criteria were built from 518 GCA cases and 536 comparison patients and then tested on a separate set of 238 GCA cases and 213 comparison patients. In that test set they correctly classified 87.0% of the real GCA cases (sensitivity) and correctly ruled out 94.8% of the patients who did not have GCA (specificity), so about 5 in 100 non-GCA patients were wrongly labelled. It is important to remember that these classification criteria were developed to ensure homogeneous patient populations in clinical trials, not to replace clinical judgment in individual patient management.

Treatment

The cornerstone of GCA treatment is immediate initiation of high-dose corticosteroids. The 2018 EULAR recommendations state: "High dose glucocorticoid therapy (40-60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active giant cell arteritis", and treatment is started without waiting when visual symptoms are present or the diagnosis is strongly suspected. For cranial GCA with visual threat — including any history of transient visual loss, established visual loss, or jaw claudication suggesting critical ischemia — the recommended starting dose is prednisone 60 mg per day (or 1 mg/kg/day, up to 60 mg). For patients presenting with acute visual loss or bilateral visual involvement, intravenous methylprednisolone 1 g per day for three consecutive days is commonly given before transitioning to oral prednisone, as this may prevent contralateral eye involvement and stabilize or occasionally partially reverse established visual loss. For patients without cranial ischemic features and without visual risk, 40 mg per day may be appropriate. Patients who present with isolated large-vessel GCA are typically managed with 40–60 mg per day depending on clinical severity.

Low-dose aspirin (75 to 100 mg per day) was once widely added to GCA treatment to prevent strokes and vision loss from narrowed arteries, on the idea that it blocks platelet clumping where the artery wall is inflamed; it has not been tested in a prospective randomized trial specifically in GCA. The 2018 EULAR update states: "We no longer recommend the routine use of antiplatelet or anticoagulant therapy for treatment of LVV unless it is indicated for other reasons" (LVV = large vessel vasculitis, the group that includes GCA).

Corticosteroids are usually tapered slowly over 12 to 24 months, guided by clinical symptoms and inflammatory markers (erythrocyte sedimentation rate, C-reactive protein). Relapse during or after taper is common, occurring in approximately 40 to 50% of patients within the first year. Relapse typically manifests as return of headache, jaw claudication, scalp tenderness, or rising inflammatory markers — not always with visual symptoms. Relapse is usually treated by restarting or raising the steroid dose. The cumulative steroid burden in GCA is substantial and causes significant morbidity in this elderly population: diabetes mellitus, osteoporotic fractures, hypertension, cataracts, infections, and avascular necrosis.

Tocilizumab (TCZ), a humanized monoclonal antibody against the interleukin-6 receptor, was approved by the U.S. Food and Drug Administration (FDA) in 2017 specifically for GCA — the first biologic agent approved for this indication — based on the landmark GiACTA trial (Stone et al., NEJM 2017; PMID 28745999). In this phase 3 randomized controlled trial, subcutaneous tocilizumab 162 mg weekly combined with a 26-week prednisone taper achieved sustained remission at 52 weeks in 56% of patients, and tocilizumab every other week in 53%, compared with 14% on placebo with a 26-week taper and 18% on placebo with a 52-week taper. The median total prednisone dose over the 52 weeks was 1,862 mg in each tocilizumab group, against 3,296 mg and 3,818 mg in the two placebo groups. Serious adverse events occurred in 14–15% of patients on tocilizumab and 22–25% on placebo (Stone 2017). Tocilizumab is now considered standard of care for patients who require steroid-sparing therapy, including those with relapsing or refractory disease, those with high-risk steroid toxicity profiles, and many physicians now use it as initial combination therapy. Supportive measures include proton pump inhibitor therapy for gastrointestinal protection, calcium and vitamin D supplementation, bisphosphonate therapy to prevent corticosteroid-induced osteoporosis, and glucose monitoring for steroid-induced hyperglycemia.

Upadacitinib: A second steroid-sparing drug, upadacitinib, a once-daily tablet that blocks Janus kinase (JAK) signalling, including signals from interleukin-6 and interferon-γ, was approved for GCA in 2025 (Schmidt 2026), and the US label lists 15 mg once daily with a tapering course of corticosteroids. In the SELECT-GCA trial of 428 people with new or relapsing GCA (70% new-onset), 46.4% of those on 15 mg with a 26-week steroid taper stayed in sustained remission at week 52, compared with 29.0% on placebo with a 52-week taper; the 7.5 mg dose (41.1%) was not better than placebo. The 15 mg dose also lengthened the time to a flare and lowered total steroid use. Safety over the 52 weeks was similar to placebo, and no major heart or blood-vessel events occurred in the upadacitinib groups (Blockmans 2025). A 2026 review notes that flares returned quickly in patients whose upadacitinib was stopped after they had reached sustained remission. The US label carries a boxed warning for serious infections, death, cancer, major heart events and blood clots (thrombosis).

GCA–PMR Overlap

Polymyalgia rheumatica and giant cell arteritis are closely related conditions that share pathophysiologic mechanisms and frequently co-occur. Forty to fifty percent of patients with GCA have concurrent PMR — characterized by bilateral aching and pronounced morning stiffness of the shoulder girdles, neck, and hip girdles — either at the time of GCA diagnosis or as a preceding or subsequent manifestation. Conversely, clinically apparent GCA develops in approximately 15 to 20% of patients diagnosed with PMR, and subclinical large-vessel vasculitis detectable on FDG-PET/computed tomography imaging may be present in a higher proportion of "pure PMR" patients without overtly clinical GCA features.

The clinical management implication of this overlap is critical: any patient with a diagnosis of PMR who subsequently develops new headache, jaw claudication, scalp tenderness, visual disturbance, or prominent constitutional symptoms is treated as urgent: doctors evaluate for GCA and start GCA-dose corticosteroids (prednisone 40 to 60 mg/day, not the lower PMR dose of 15 to 20 mg) while temporal artery biopsy or imaging is awaited. Treating a patient with underlying GCA at only the PMR dose of corticosteroids is inadequate to prevent ischemic complications, including irreversible vision loss. This distinction between the treatment doses for PMR alone versus GCA is one of the most practically important points in rheumatologic emergency management.

Prognosis and Monitoring

Visual loss due to anterior ischemic optic neuropathy is the most devastating acute complication of GCA and is almost always permanent once established. With prompt high-dose corticosteroid treatment initiated before optic nerve infarction occurs, the risk of visual loss is reduced to below 5%; in untreated or delayed-treatment patients, visual loss occurs in 15 to 20%. Contralateral eye involvement — sometimes occurring within days of the first eye — is a particular concern and underscores the urgency of intravenous (IV) methylprednisolone in patients with any established visual loss. Aortic aneurysm, primarily thoracic, represents a significant late complication: patients with GCA have a 2- to 3-fold increased lifetime risk of aortic aneurysm compared with the general population, with most cases presenting 5 to 10 years after the initial GCA diagnosis. Current guidelines recommend surveillance imaging (computed tomography angiography or MRA) of the thoracic aorta at approximately 5 years after diagnosis to detect aortic dilation before rupture or dissection.

The disease typically follows a chronic relapsing-remitting course over 2 to 5 years, after which many patients are able to taper and discontinue corticosteroids entirely. Relapse risk is highest during the first 2 years of taper, particularly when the prednisone dose falls below 10 to 15 mg per day. Inflammatory markers (erythrocyte sedimentation rate and C-reactive protein) are monitored regularly during the taper — rising markers in an asymptomatic patient warrant caution and close follow-up, though asymptomatic marker elevation alone does not always mandate dose escalation in a clinically stable patient. Tocilizumab masks the elevation of C-reactive protein (a direct downstream effect of interleukin-6 (IL-6) blockade) and renders C-reactive protein unreliable as a disease activity marker in patients on this biologic; clinical symptoms become the primary guide to relapse detection in tocilizumab-treated patients. Long-term steroid-related morbidity — diabetes, osteoporosis, infections, cataracts, and cardiovascular disease — often exceeds the direct morbidity of the vasculitis itself in elderly GCA patients, making steroid-sparing strategies a high priority from the outset of treatment.

Key Research Papers

  1. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371(1):50–57. — PubMed PMID: 24988557
  2. Stone JH, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–328. — PubMed PMID: 28745999
  3. Dejaco C, et al. 2015 Recommendations for the management of polymyalgia rheumatica. Ann Rheum Dis. 2015;74(10):1799–1807. — PubMed PMID: 26359488
  4. Hellmich B, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19–30. — PubMed PMID: 31270110
  5. Dasgupta B, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594–1597. — PubMed PMID: 20371504 (superseded by the 2020 British Society for Rheumatology guideline below)
  6. Salvarani C, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347(4):261–271. — PubMed PMID: 12140303
  7. Muratore F, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford). 2015;54(3):463–470. — PubMed PMID: 25193809
  8. Hayreh SS, et al. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol. 1997;123(3):285–296. — PubMed PMID: 9063237
  9. Gonzalez-Gay MA, et al. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore). 2005;84(5):269–276. — PubMed PMID: 16148727
  10. Proven A, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49(5):703–708. — PubMed PMID: 14558057
  11. Cid MC, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum. 1998;41(1):26–32. — PubMed PMID: 9433866
  12. Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Care Res (Hoboken). 2021;73(8):1071–1087. — PubMed PMID: 34235871
  13. Mackie SL, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology (Oxford). 2020;59(3):487–494. — PubMed PMID: 31970410
  14. Ponte C, et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis. 2022;81(12):1647–1653. — PubMed PMID: 36351706
  15. Blockmans D, et al. A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. N Engl J Med. 2025;392(20):2013–2024. — PubMed PMID: 40174237
  16. Schmidt WA. Treatment of giant cell arteritis: focus on upadacitinib. Expert Opin Pharmacother. 2026;27(5):397–407. — PubMed PMID: 41923480
  17. US National Library of Medicine, DailyMed. Upadacitinib extended-release tablets: prescribing information (section 1.9 Giant Cell Arteritis; boxed warning). Revised 6/2026. — DailyMed

Back to Table of Contents

Connections